SCHEMBL26260736

SCHEMBL26260736

FC(F)(F)c1cc(OCc2nc3cc(Nc4ccccc4Cl)ccc3[nH]2)ccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ RAB9A P51151 5/20 0.40
▸ NPC1 O15118 4/20 0.40
▸ TP53 P04637 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PDE10A Q9Y233 2/20 0.40
▸ AURKA O14965 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041208 1.00 SMN1; SMN2 (0.45) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL30041546 0.90 RAB9A (0.41) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL26260731 0.90 RAB9A (0.41) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL25400113 0.88 RAB9A (0.44) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL30040122 0.88 RAB9A (0.44) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL26260734 0.83 NPC1 (0.40) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL26260644 0.83 NPC1 (0.40) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL21614711 0.80 RAB9A (0.45) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL21612019 0.77 RAB9A (0.49) SMN1; SMN2MEN1LMNAKMT2AALDH1A1
SCHEMBL30579944 0.77 RAB9A (0.43) SMN1; SMN2MEN1LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286942-A1 NEW PqsR INVERSE AGONISTS QRFPR, P2RY11, GPR55 SMN1; SMN2 4177/4885MEN1 2836/4885LMNA 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback